First-ever approved dermatomyositis therapy just launched; commercial uptake now determines whether a multi-indication TYK2/JAK1 platform compounds or stalls

Roivant Sciences is a commercial-stage biopharmaceutical company with one approved product, LISRAYA, which treats dermatomyositis and became the first approved therapy for this disease in August 2026.

LISRAYA's August 2026 approval as the first targeted therapy for dermatomyositis, combined with a $3.8 billion cash position supporting runway into profitability, gives Roivant a rare commercial anchor to fund a four-indication brepocitinib expansion and a Phase 3 IMVT-1402 program across myasthenia gravis, Graves' disease, and CIDP. The thesis resolves on whether LISRAYA captures meaningful dermatomyositis market share while brepocitinib's Phase 3 trials in cutaneous sarcoidosis and non-infectious uveitis confirm the platform. Batoclimab's dual Phase 3 failure in thyroid eye disease is a reminder that positive Phase 2 data does not guarantee registration, and IMVT-1402 now carries the FcRn franchise alone.